Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives

Dow Jones

Apr 10, 2025

By Sabela Ojea

Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements.

Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months.

The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process.

"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner," Chief Executive Stephen Brady said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

April 09, 2025 17:01 ET (21:01 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2526346401"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2526346401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2526346401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-10 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526346401","market":"sh","top_or_hot":-1,"title":"Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. \n</p>\n<p>\n  Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months. \n</p>\n<p>\n  The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process. \n</p>\n<p>\n  \"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner,\" Chief Executive Stephen Brady said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 09, 2025 17:01 ET (21:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempest Therapeutics Seeks Partner as It Explores Strategic Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-10 05:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. \n</p>\n<p>\n  Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months. \n</p>\n<p>\n  The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process. \n</p>\n<p>\n  \"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner,\" Chief Executive Stephen Brady said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 09, 2025 17:01 ET (21:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2526346401","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526346401","pubTimestamp":1744232460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements.Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months.The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process.\"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner,\" Chief Executive Stephen Brady said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","BK4139":"生物科技","TPST":"Tempest Therapeutics Inc."},"translate_title":"Tempest Therapeutics寻求合作伙伴以探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":0.9,"LENZ":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. \n\n\n  Shares rose 9.2% to $7.81 in post-market trading. Through Wednesday's close, the stock has fallen 85% over the past 12 months. \n\n\n  The clinical-stage biotechnology company on Wednesday said that it hired MTS Health Partners as financial adviser for its strategic evaluation process. \n\n\n  \"Given the positive data and commercial potential with this [company] pipeline, as well as the clearance from the Food and Drug Administration on the lead program's pivotal study, we believe this is a rare opportunity for a partner,\" Chief Executive Stephen Brady said. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 17:01 ET (21:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}